Next Generation Sequencing (NGS) is a powerful, flexible, and indispensable biological tool that is used in several areas of biological study. NGS technologies help in generating genome-wide sequence data in a couple of days. These technologies are highly parallelized allowing to sequence thousands to millions of molecules at the same time. The main advantage of these platforms is determination of the sequenced data from amplified single DNA fragments, avoiding the need for cloning of DNA fragments.

Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/158

NGS has large number of applications, enabling rapid technological advances across several fields in biological science. The technology has enabled researchers to gain significant knowledge in public health studies and epidemiology, to sequence viruses and bacteria and help detect causes that may contribute to virulence. Furthermore, in gene expression research, next generation sequencing of RNA replace microarray analysis, allowing researchers to see RNA expression sequence. This RNA sequencing can provide information on entire transcriptome in one analysis, irrespective of any previous knowledge of genetic sequence.

The global next generation sequencing market was valued at US$ 5.6 billion in 2017 and is expected to witness a robust CAGR of 18.1% over the forecast period (2017–2025).

Rising demand for early detection of cancer and infectious diseases to drive growth of the NGS market

The chances of successful treatment increase when cancer and infectious diseases are detected at the early stage. One of the major factors that drive growth of the next generation sequencing market is the rising prevalence of cancer and other infectious diseases. According to the World Health Organization (WHO), in 2012, new cases of cancer was around 14 million and the incidence is estimated to increase to 70% by 2030.

As per statistics published by National Cancer Institute (NCI), in 2016, 1,685,210 new cases of cancer were diagnosed in the U.S. alone. In 2015, WHO reported 8.8 million deaths occurred due to cancer. According to American Cancer Society (ACS), in 2017, around 161,360 cases of prostate cancer were reported in the U.S alone. ACS, in 2015, also reported 4.5 million new cancer cases in China and the number is expected to increase to 7.6 Mn by 2020. Morbidity cases in tuberculosis, salmonella, and meningococcal disease was as high as 90,000 in the U.S. in 2016. Therefore, increasing demand for early diagnosis of cancer and infectious diseases, to aid in better outcome, is in turn expected to aid in growth of the market over the forecast period.

Market Dynamics

Major factors driving growth of the next generation sequencing market are early detection of cancer and infectious diseases and increasing partnership among academic and industry partnerships for research and development. For academic institutions, these collaborations help in commercialization of their discoveries from basic research to medical products. For instance, in March, 2018, Cofactor Genomics, a U.S.-based developer of Cofactor Paragon (RNA analysis tool) signed agreement with National Cancer Institute, and other three other pharma and academic institutes to show clinical ability of its product.

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/158

Key companies covered as a part of this study include Thermo Fisher Scientific Inc., Agilent Technologies, Inc., BioMerieux S.A., F. Hoffmann-La Roche Ltd, Qiagen N.V., Illumina, Inc., Oxford Nanopore Technologies, and Beijing Genomics Co. Ltd.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]